Skip to main content
An official website of the United States government
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

Datopotamab-Deruxtecan for the Treatment of Patients with HER2 Negative Breast Cancer with Brain Metastasis

Trial Status: active

This phase II trial tests how well datopotamab deruxtecan works in treating patients with HER2 negative breast cancer that has metastasized to the brain. Datopotamab deruxtecan is a type of anti-cancer drug called an “antibody drug conjugate” (ADC) that targets cancer cells expressing a specific molecule on the tumor cell membrane. One part is a protein called a monoclonal antibody (datopotamab, or dato) that recognizes and attaches to cells that have a specific protein called TROP2 on their surface. Another part contains a chemotherapy like molecule called DXd. When datopotamab deruxtecan binds to a TROP2 protein on a cancer cell, the drug is internalized in the tumor cell, the link breaks off, and DXd is released into the cancer cell, damaging or killing it.